YOLFTbeta
Neovici Holding AB (publ)

Neovici Holding AB (publ)

IDLDX · ST · Healthcare / Diagnostics & Research

0.316SEK-0.02 (-5.67%)

Price History

Full chart

Market Stats

Previous Close0.335
Open0.333
Day Range0.314 – 0.344
52-Week Range0.25 – 0.53
Volume202.47K
Market Cap85.23M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta0.94
50-Day Avg0.3989
200-Day Avg0.3822

About

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Gustav Sten
  • Employees25
  • HeadquartersKarlsbodavAegen 39, Stockholm, Sweden, 168 67, Sweden
  • Websitehttps://idldiagnostics.com

Leadership

  • Mr. Gustav StenChief Executive Officer
  • Ms. Ellen DittbernerChief Finance Officer
  • Ms. Maria SundbergChief Operations Officer
  • Ms. Leyla Ali DholeyChief Scientific Officer
  • Ms. Jocelyn AkerbergChief Quality Officer

Financials

Income Statement

Currency: SEK2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue26.85K----460.22K54.61K502.03K781.84K442.70K84.00K12.00M36.99M43.04M57.44M53.11M
Growth (%)-------88.13%+819.37%+55.73%-43.38%-81.03%+14180.95%+208.32%+16.37%+33.45%-7.54%
Cost of Revenue--15.13K----276.15K1.25M372.19K21.00K17.04M39.09M45.14M45.70M25.39M
Gross Profit26.85K--15.13K--460.22K54.61K225.88K-469.71K70.51K63.00K-5.04M-2.10M-2.10M11.73M27.72M
Gross Margin100.00%----100.00%100.00%44.99%-60.08%15.93%75.00%-42.06%-5.69%-4.88%20.43%52.19%
Operating Expense2.12M-3.13M--7.94M9.28M17.49M20.29M20.81M24.11M45.53M57.20M57.68M55.16M38.44M
Operating Income-2.09M-3.50M-3.15M-3.72M-6.41M-7.48M-9.23M-17.27M-20.76M-20.74M-24.05M-50.57M-59.30M-59.78M-43.43M-10.72M
Operating Margin-7786.78%-----1626.31%-16900.68%-3439.30%-2654.82%-4683.93%-28633.33%-421.58%-160.34%-138.91%-75.61%-20.19%
EBITDA-2.02M-3.47M-3.06M-3.65M-6.30M-7.46M-9.22M-15.01M-20.51M-20.47M-23.73M-30.26M-12.11M-13.76M-33.53M-8.07M
EBITDA Margin-7534.60%-----1620.43%-16886.19%-2989.02%-2623.51%-4624.45%-28250.00%-252.28%-32.75%-31.97%-58.39%-15.20%
Net Income-2.15M-3.58M-3.16M-3.73M-6.37M-7.48M-9.23M-17.27M-20.76M-16.20M-19.46M-50.03M-58.97M-59.30M-42.45M-12.15M
Net Income Margin-8014.58%-----1625.10%-16911.96%-3440.16%-2654.89%-3659.83%-23165.48%-417.02%-159.45%-137.78%-73.91%-22.88%
R&D------2.07M7.71M9.85M9.51M12.60M19.83M24.43M25.24M22.79M13.59M
R&D as % of Total Revenue------3791.57%1534.85%1260.48%2148.91%14995.24%165.29%66.04%58.65%39.68%25.60%
Interest Expense61.18K79.88K72.18K47.42K37.66K14.47K6.05K1.46K574452-1.00K5.00K13.00K3.00K445.00K
Interest Expense % of Total Revenue227.81%----3.14%11.08%0.29%0.07%0.10%-0.01%0.01%0.03%0.01%0.84%

Balance Sheet

Currency: SEK2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.64M7.02M11.98M18.05M38.60M74.32M66.42M49.51M57.42M91.37M60.48M227.41M236.01M174.89M134.13M176.86M
Total Liabilities2.43M2.22M1.83M2.27M2.88M1.63M2.97M2.84M2.90M10.97M4.22M9.96M13.32M11.25M12.93M28.70M
Total Equity1.20M4.80M10.15M15.77M35.72M72.69M63.46M46.68M54.51M80.41M56.26M213.52M222.69M163.65M121.20M148.16M
Cash591.93K1.73M4.18M5.00M18.51M49.70M32.85M17.25M29.73M13.63M42.01M18.40M65.19M50.72M47.78M36.57M
Total Debt1.00M650.00K550.00K350.00K150.00K399.78K---------13.24M
Net Debt408.07K-1.08M-3.63M-4.65M-18.36M-49.30M-32.85M-17.25M-29.73M-13.63M-42.01M-18.40M-65.19M-50.72M-47.78M-23.34M

Cash Flow

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.59M----9.13M-7.17M-15.24M-16.41M-15.06M-18.90M-28.21M-13.69M-13.44M-2.36M-7.60M
Investing Cash Flow-2.88M----3.98M-9.68M-367.92K--244.96K-53.00K4.54M-10.12M-1.28M-581.00K-1.55M
Financing Cash Flow6.61M---44.30M--28.89M-803.00K47.34M-70.60M250.00K--2.06M
Capital Expenditure00003.98M9.68M317.92K0244.96K53.00K370.00K4.06M498.00K581.00K1.55M
Free Cash Flow-2.59M----13.11M-16.85M-15.55M-16.41M-15.30M-18.95M-28.58M-17.75M-14.71M-2.36M-9.15M
FCF to OCF100.00%---143.65%235.09%102.09%100.00%101.63%100.28%101.31%129.63%109.52%100.00%120.46%

Earnings

Report DateJun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------------------------------
EPS Actual-0.15-0.06-0.12-0.06-0.07-0.04-0.06-0.05-0.06-0.03-0.08-0.05-0.07-0.05-0.17-0.10-0.07-0.07-0.05-0.10-0.07-0.09-0.06-0.14-0.12-0.12-0.19-0.14-0.14-0.13-0.13-0.13-0.12-0.11-0.15-0.08-0.08-0.08-0.08-0.08-0.09-0.16-0.17-0.09-0.07-0.05-0.07-0.06-0.07-0.06-0.07-0.05-0.06-0.04-0.04-0.05-0.06-0.01-0.010.01-0.00
Surprise-------------------------------------------------------------
Timing-------------------------------------------------------------

Key Statistics & Ratios

Market Cap85.23M
Enterprise Value63.46M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.45
Price / Book0.58
EPS-0.02
Book Value0.644
Revenue (TTM)58.95M
Gross Profit (TTM)34.51M
EBITDA-2.97M
Profit Margin-7.49%
Operating Margin-8.14%
Return on Equity-3.64%
Return on Assets-1.83%
Shares Outstanding230.36M
Shares Float113.52M
Beta0.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%